Journals / Ahi Evran Tıp Dergisi / 2021 / Cilt: 5 Sayı: 1

A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.

Covid 19 Pandemisi Sırasında Kullanılan Farmakolojik Ajanların Gözden Geçirilmesi.

Pages
61–72
Publication Date
2021-04-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies and information are needed on these drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A number of pneumonia cases have been reported in China since December 2019.
📊
Key Findings & Data:After a series of researches, the World Health Organization named this disease caused by 2019-nCoV on 11 February 2020 as coronavirus disease (COVID-19).
💡
Conclusion & Impact:Further studies and information are needed on these drugs.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:KOVİD-19 · ilaç · farmakodinamik

Abstract

A number of pneumonia cases have been reported in China since December 2019. After a series of researches, the World Health Organization named this disease caused by 2019-nCoV on 11 February 2020 as coronavirus disease (COVID-19). COVID-19 is a global pandemic. The aim of this review was to evaluate the pharmacokinetics and pharmacodynamics of the drugs used in COVID-19 pandemic.Evidence for eficacy of the drugs used in the COVID-19 pandemic is not yet clear. Further studies and information are needed on these drugs.

Özet

2019 Aralık ayından itibaren Çin’de bir dizi pnomöni vakası bildirildi. Dünya Sağlık örgütü yapılan bir dizi araştırmadan sonra 11 Şubat 2020 de 2019- nCoV’un neden olduğu bu hastalığı koronavirüs hastalığı (COVID-19) olarak adlandırdı. COVID-19 küresel bir salgındır. Bu derlemede COVID-19 pandemisinde kullanılan ilaçların farmakokinetik ve farmakodinamik olarak değerlendirilmesi amaçlanmıştır. COVID-19 pandemisinde kullanılan ilaçlar ile ilgili kanıtlar henüz kesin değildir. Bu ilaçlar ile ilgili daha çok çalışmaya ve daha çok bilgiye ihtiyaç duyulmaktadır.

🔖

Cite This Article

ÖZATİK, F. Y. (2021). A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. Ahi Evran Tıp Dergisi, Cilt: 5 Sayı: 1, 61–72. https://ajindex.com/articles/898897

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARSCoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020;63(4):119-124
  2. Kim KH. COVİD-19. Int Neurourol J. 2020;24(1):1-1
  3. Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020;28(2):198-201
  4. Aguiar ACC, Murce E, Cortopassi WA, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459-464
  5. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J. Gen. Virol. 1969;4(2):203-214
  6. Keyaerts E, Li S, Vijgen L, Verbeeck J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416-3421
  7. Tan YW, Yam WK, Sun J, Chu JJI. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antivir Res. 2018;149(2018):143-149
  8. Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine. 2017;24:189-194
  9. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300-302
  10. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect. Dis 2011;11(9):677-683
  11. Delogu I, de Lamballerie X. Chikungunya disease and chloroquine treatment. J Med Virol. 2011;83(6): 1058-1059
  12. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011;23(3):278-281
  13. Şimşek Yavuz S, Ünal S. Antiviral Treatment of COVID-19. Turk J Med Sci. 2020;50:611-619
  14. Schrezenmeie T, Dörner E. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 2020;16:155-166
  15. Lu YL, Chen CC, Chang MY. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-536
  16. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndr